Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Cytokinetics Inc (CYTK)  
$58.44 0.52 (0.88%) as of 4:30 Fri 10/17


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 144,135,000
Market Cap: 8.42(B)
Last Volume: 8,264,325 Avg Vol: 8,201,370
52 Week Range: $29.84 - $62.8
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  1083
Guru Rank Value     : 0
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 64,358 144,109 394,079 892,754
Total Sell Value $3,205,522 $6,009,242 $17,272,680 $47,633,582
Total People Sold 4 7 8 10
Total Sell Transactions 16 33 69 119
End Date 2025-07-20 2025-04-18 2024-10-18 2023-10-19

   
Records found: 924
  Page 1 of 37  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Blum Robert I President & CEO   •       •      –    2025-10-16 4 S $60.03 $300,150 D/D (5,000) 363,108     -
   Wysenski Nancy Director   •       •      –    2025-10-15 4 A $62.80 $6,217 D/D 99 30,873     -
   Henderson John T Director   •       •      –    2025-10-15 4 A $62.80 $21,226 D/D 338 74,578     -
   Kaye Edward M. Md Director   •       •      –    2025-10-15 4 A $62.80 $12,497 D/D 199 9,977     -
   Harrington Robert Arthur Director   •       •      –    2025-10-15 4 A $62.80 $12,497 D/D 199 20,692     -
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-10-07 4 S $60.56 $121,120 D/D (2,000) 140,610 2%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-10-07 4 OE $10.60 $21,200 D/D 2,000 142,610     -
   Kaye Edward M. Md Director   •       •      –    2025-10-06 4 S $60.00 $405,420 D/D (6,757) 9,778 3%     
   Blum Robert I President & CEO   •       •      –    2025-10-01 4 S $55.05 $275,250 D/D (5,000) 368,108 -6%     
   Kaye Edward M. Md Director   •       •      –    2025-09-30 4 S $55.08 $368,761 D/D (6,695) 16,535 -7%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-09-23 4 S $49.28 $98,560 D/D (2,000) 140,610 -21%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-09-23 4 OE $10.60 $21,200 D/D 2,000 142,610     -
   Blum Robert I President & CEO   •       •      –    2025-09-15 4 S $49.77 $248,850 D/D (5,000) 373,108 -19%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-09-09 4 S $51.29 $102,580 D/D (2,000) 140,610 -14%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-09-09 4 OE $10.60 $21,200 D/D 2,000 142,610     -
   Blum Robert I President & CEO   •       •      –    2025-09-02 4 S $48.76 $243,800 D/D (5,000) 378,108 -19%     
   Harrington Robert Arthur Director   •       •      –    2025-09-02 4 S $48.67 $104,641 D/D (2,150) 20,493 -19%     
   Kaye Edward M. Md Director   •       •      –    2025-09-02 4 S $50.00 $337,800 D/D (6,756) 23,230 -19%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-08-19 4 S $38.31 $76,620 D/D (2,000) 140,610 -56%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-08-19 4 OE $10.60 $21,200 D/D 2,000 142,610     -
   Blum Robert I President & CEO   •       •      –    2025-08-15 4 S $38.42 $192,100 D/D (5,000) 383,108 -52%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-08-05 4 S $36.34 $72,680 D/D (2,000) 140,610 -63%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-08-05 4 OE $10.60 $21,200 D/D 2,000 142,610     -
   Blum Robert I President & CEO   •       •      –    2025-07-29 4 S $36.45 $182,250 D/D (5,000) 388,108 -64%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-07-22 4 S $37.47 $74,940 D/D (2,000) 140,610 -56%     
  924 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 37
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2025 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us